- Home
- ABBV vs MRK Comparison
ABBV vs MRK Comparison
Compare ABBV & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABBV
- MRK
- Stock Information
- Founded
- ABBV 2012
- MRK 2000
- Country
- ABBV United States
- MRK United States
- Employees
- ABBV N/A
- MRK N/A
- Industry
- ABBV Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- ABBV Health Care
- MRK Health Care
- Exchange
- ABBV Nasdaq
- MRK Nasdaq
- Market Cap
- ABBV 365.1B
- MRK 218.8B
- IPO Year
- ABBV N/A
- MRK N/A
- Fundamental
- Price
- ABBV $231.49
- MRK $86.24
- Analyst Decision
- ABBV Buy
- MRK Buy
- Analyst Count
- ABBV 22
- MRK 15
- Target Price
- ABBV $232.05
- MRK $105.14
- AVG Volume (30 Days)
- ABBV 6.4M
- MRK 13.0M
- Earning Date
- ABBV 10-31-2025
- MRK 10-30-2025
- Dividend Yield
- ABBV 2.86%
- MRK 3.82%
- EPS Growth
- ABBV N/A
- MRK 20.41
- EPS
- ABBV 2.10
- MRK 6.49
- Revenue
- ABBV $58,328,000,000.00
- MRK $63,616,000,000.00
- Revenue This Year
- ABBV $9.85
- MRK $1.84
- Revenue Next Year
- ABBV $8.98
- MRK $5.24
- P/E Ratio
- ABBV $109.31
- MRK $13.07
- Revenue Growth
- ABBV 6.05
- MRK 1.82
- 52 Week Low
- ABBV $163.81
- MRK $73.31
- 52 Week High
- ABBV $244.81
- MRK $110.19
- Technical
- Relative Strength Index (RSI)
- ABBV 59.40
- MRK 55.87
- Support Level
- ABBV $225.32
- MRK $83.16
- Resistance Level
- ABBV $234.68
- MRK $85.50
- Average True Range (ATR)
- ABBV 4.78
- MRK 2.08
- MACD
- ABBV -1.05
- MRK -0.15
- Stochastic Oscillator
- ABBV 31.61
- MRK 40.03
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).